ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2017
Physical Health and Drug Safety in Individuals with Schizophrenia.
Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04366401 (Efficacy of Dietary Modulation With High Prebiotic and Probiotic Content on Nutritional and Metabolic Status in Schizophrenia Spectrum Disorders), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Dietary Modulation With High Prebiotic and Probiotic Content on Nutritional and Metabolic Status in Schizophrenia Spectrum Disorders
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Initial physical health assessment for psychosis in Australia and New Zealand: 2026 recommendations.The Australian and New Zealand journal of psychiatry · 2026Guideline
- [Use of psychoactive substances as a treatment for psychosis].Revista de neurologia · 2023Pooled it
- Impact of high prebiotic and probiotic dietary education in the SARS-CoV-2 era: improved cardio-metabolic profile in schizophrenia spectrum disorders.BMC psychiatry · 2022Trial
- Testing the Transportability of the Psychosis Metabolic Risk Calculator in Canada (Quebec): International External Validation Study.Schizophrenia bulletin · 2026Article
- Psychopharmacological Treatment in Patients with Heart Failure: A Narrative Review of Mood Stabilizers and Antipsychotics.Brain sciences · 2026Review
- Metabolic monitoring among patients with psychotic disorders taking antipsychotics: results of a quality improvement project to address this challenging guideline-practice gap.BMJ open quality · 2025Article
- Changes in Antipsychotic Medication Adherence Among Medicaid Beneficiaries with Schizophrenia During COVID-19.Administration and policy in mental health · 2025Article
- Breaking Barriers Transforming Primary Care to Serve the Physical Health Needs of Individuals With SMI in the NHS.International journal of mental health nursing · 2025Review
- Inequity in cardiometabolic hospital admissions and blood screening in New Zealand Indigenous Māori with psychosis.BJPsych open · 2024Article
- Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Severity in schizophrenia patients receiving atypical antipsychotic medications.Bioinformation · 2022Article
- Efficacy of nutrition education for the increase of symbiotic intake on nutritional and metabolic status in schizophrenic spectrum disorders: A two-arm protocol.Frontiers in nutrition · 2022Article
- Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.Neuropsychiatric disease and treatment · 2022Article
- Article
- The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample.Frontiers in psychiatry · 2020Article
- Understanding Engagement with a Physical Health Service: A Qualitative Study of Patients with Severe Mental Illness.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2019Article
- Clozapine, elevated heart rate and QTc prolongation.Journal of psychiatry & neuroscience : JPN · 2018Article
- Influence of the use of atypical antipsychotics in metabolic syndrome.Revista espanola de sanidad penitenciariaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require the attention and care of prescribers.
methodsWe used the ADAPTE process to adapt existing guideline recommendations from the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines on the dosing of antipsychotics and antipsychotic polypharmacy, screening for adverse effects of antipsychotics, and management of metabolic and extrapyramidal side effects to the Canadian context.
resultsPrescribers are encouraged to use the lowest effective dose and to avoid the routine use of multiple antipsychotics. Scheduled monitoring of body mass index, waist circumference, blood pressure, glucose, lipids, prolactin, electrocardiograms, and extrapyramidal symptoms is recommended. Lifestyle interventions are recommended to mitigate antipsychotic-induced weight gain. Prescribers should follow Canadian guidelines on the treatment of obesity, dyslipidemia, and diabetes. Recommendations on antipsychotic drug choice are made for users particularly concerned about extrapyramidal symptoms.
conclusionCareful monitoring and attention by prescribers may mitigate adverse effects associated with antipsychotic medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.